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Abstract
Psoriasis is characterized by hyperproliferation of keratinocytes and by infiltration of activated Th1 and Th17 cells in the
(epi)dermis. By expression microarray, we previously found the GATA3 transcription factor significantly downregulated in
lesional psoriatic skin. Since GATA3 serves as a key switch in both epidermal and T helper cell differentiation, we
investigated its function in psoriasis. Because psoriatic skin inflammation shares many characteristics of epidermal
regeneration during wound healing, we also studied GATA3 expression under such conditions. Psoriatic lesional skin
showed decreased GATA3 mRNA and protein expression compared to non-lesional skin. GATA3 expression was also
markedly decreased in inflamed skin of mice with a psoriasiform dermatitis induced with imiquimod. Tape-stripping of non-
lesional skin of patients with psoriasis, a standardized psoriasis-triggering and skin regeneration-inducing technique,
reduced the expression of GATA3. In wounded skin of mice, low GATA3 mRNA and protein expression was detected. Taken
together, GATA3 expression is downregulated under regenerative and inflammatory hyperproliferative skin conditions.
GATA3 expression could be re-induced by successful narrow-band UVB treatment of both human psoriasis and imiquimod-
induced psoriasiform dermatitis in mice. The prototypic Th2 cytokine IL-4 was the only cytokine capable of inducing GATA3
in skin explants from healthy donors. Based on these findings we argue that GATA3 serves as a key regulator in psoriatic
inflammation, keratinocyte hyperproliferation and skin barrier dysfunction.
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Introduction
Psoriasis is a very common chronic inflammatory skin disease
characterized by sharply demarcated, thick, red, scaly plaques.
Histologically it is characterized by epidermal acanthosis, papillo-
matosis and parakeratosis, infiltrating leukocytes and neutrophils in
the epidermis and dermis, and neoangiogenesis.
In psoriasis, altered keratinocyte differentiation is characterized
by downregulation of late keratinocyte differentiation markers and,
upregulation of early differentiation markers [1], accompanied by
an increase in the pool of proliferating keratinocytes. The alterations
in keratinocyte proliferation and differentiation lead to impairment
of the skin barrier function, and this barrier impairment correlates
with the severity of the disease [2].
The factors controlling keratinocyte hyperproliferation and the
disturbed keratinocyte differentiation in psoriasis remain incom-
pletely understood. Hyperproliferation in psoriasis and prolifera-
tion in cancers share many characteristics, such as the induction of
similar oncogenes and transcription factors [3]. Previous micro-
array studies assessing altered biological pathways in psoriasis
consistently showed that mRNA encoding the transcription factor
GATA3 was significantly downregulated in lesional psoriatic
keratinocytes, and was re-induced by successful therapy [4], [5].
GATA3 is a transcription factor with two zinc finger motifs that
binds to a six-nucleotide consensus sequence (A/T)GATA(A/G)
[6]. In the skin, GATA3 is expressed in the epidermis and in the
inner root sheath of the hair follicle [7] where it serves as a
regulator of inner root cell lineage formation of the hair follicle,
postnatal hair growth and maintenance [8,9]. GATA3 is essential
for correct formation of the epidermal barrier, in the regulation of
epidermal differentiation and desquamation via activation of
kallikrein 1 [10,11]. In mice, complete GATA3 deficiency is
incompatible with life. In the skin of epidermis-specific GATA3-
deficient mice, production of antimicrobial peptides, such as b-
defensins and S100A proteins is upregulated [9,10]. In addition,
GATA3 is abundantly expressed in the developing nervous system,
inner ear, the eye, skin, mammary glands, embryonic kidney and
thymus [8,9,12,13,14]. In cells of hemopoietic origin, GATA3
expression is confined to the T, NK and NKT cell lineages [15].
During lymphoid cell development, GATA3 is involved in T
cell commitment [16]. Functional T helper cell subset differenti-
ation into Th2 is induced by GATA3 via a STAT6-dependent
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route [17,18], [19], [20]. Polymorphisms in the Th2 cytokine
genes IL-4 and IL-13 have been reported in psoriasis [21],
indicating that not only a dominant Th1/Th17 axis but also a
defective Th2 axis can affect the disease.
As psoriasis is characterized by altered keratinocyte proliferation
and differentiation and by infiltration of activated Th1 and Th17
cells, processes that are linked to altered GATA3 expression, we
hypothesized that epithelial GATA3 might play an important role
in the pathogenesis of psoriasis. Moreover, psoriasiform epidermal
abnormalities, such as epidermal hyperplasia and hyperkeratosis,
increased innate immunity and decreased lipid biosynthesis have
been reported in mice with an epidermis-specific deletion of
GATA3 [9,10]. We wanted to determine the place of keratinocyte-
derived GATA3 during the pathological changes in psoriatic skin.
For this we studied different models of psoriasis, such as the
imiquimod-induced psoriasis-like skin inflammation in mice [22]
and ex vivo-stimulated human skin explants, and investigated
GATA3 expression and activation in keratinocytes during
epidermal regeneration, which is known to share many charac-
teristics with psoriatic skin inflammation [23]. Furthermore, we
compared gene expression changes in psoriasis and in epidermis-
specific GATA3-knock-out mice, and searched for factors that can
correct the downregulated GATA3 expression in psoriasis.
Materials and Methods
Ethics statement
Written approval was obtained for all human and animal
experimental work. The work protocol including patients with
psoriasis was approved by the Medical Ethical Committee of the
Erasmus University Medical Center Rotterdam, the Netherlands,
approval number was METC 234.237/2003/210. Collection of
skin samples after breast reduction surgery was approved by the
Medical Ethical Committee of the Erasmus University Medical
Center Rotterdam, the Netherlands, approval number was METC
140.050/SPO/1990/30 and 140.050, MEC99.785. Written in-
formed consent was obtained from all patients and healthy subjects
involved in the study. All animal work was approved by the Animal
Ethical Committee of the Erasmus University Medical Center
Rotterdam, the Netherlands, under approval number DEC EUR
851 (OZP 128-06-07). All these approvals were written.
Patients, NB-UVB treatment and biopsy samples
Sixteen patients (10 men, 6 women, age range 20–73) with
psoriasis were recruited after written informed consent (METC
registration number 234.237/2003/210). All patients had a
Psoriasis Area and Severity Index (PASI) scores of at least 10,
no systemic therapy for at least one month or topical therapy for at
least two weeks prior to the start of the study. Ten patients were
treated with standard NB-UVB phototherapy until total clearance
of psoriasis was reached, or for a maximum of three months. From
10 of these patients three-mm biopsies were taken from lesional
and non-lesional skin before the start of NB-UVB therapy and
after the last treatment session. When PASI scores reached a
reduction of 50% of the baseline score, additional biopsies from
lesional and non-lesional skin were taken. NB-UVB treatment was
applied three times weekly using a Waldmann 7001 UVB cabinet
equipped with Philips TL-01 bulbs. Starting UVB dose was 0.1–
0.3 J/cm2 (depending on the skin type of the patient); the mean
cumulative UVB dose was 42.0 J/cm2 (range 30–60 J/cm2).
During the course of UVB treatment PASI scores were evaluated
every two weeks.
From six patients biopsy samples were taken from non-lesional
skin, from which the stratum corneum was removed by tape
stripping [24,25,26]. Five hours after tape stripping biopsies were
taken from the tape-stripped area.
Skin organ culture
Skin biopsies (3 mm diameter) were obtained, after informed
consent, from healthy volunteers undergoing breast reduction in
the Department of Plastic Surgery of the Sint Franciscus Gasthuis,
Rotterdam, the Netherlands. Biopsies were cultured in a transwell
system as described previously, with the dermis immersed in
medium, and the epidermis exposed to the air interface [27].
Recombinant human IL-4 (100 ng/ml, Peprotech, Rocky Hill,
New Jersey), IFN-a (500 U/ml), IFN-c (500 U/ml) or IL-22
(50 ng/ml) (all R&D Systems, Abingdon, UK) were added to the
culture medium. These concentrations were previously demon-
strated to yield optimal biological responses in this organ culture
system. Biopsies were collected 24 h later.
Keratinocyte culture
Primary human epidermal keratinocytes were obtained from
healthy donors as described previously [28] and cultured in
Dermalife medium (LifeLine Cell Technology, Walkersville, MD)
and transferred to Lab-Tek Chamber slides. Keratinocytes from
passages 3 to 4 were used. Cells were cultured with or without CaCl2
(final Ca2+ concentration was 1.2 mM). High Ca2+ conditions were
applied in order to stimulate differentiation. In addition, TGF-b1
was added to the cells at a concentration of 3 ng/ml. Keratinocytes
were harvested after 24 h, fixed and stained with anti-GATA3
antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA).
RNA isolation
The epidermis was separated from the dermis after incubation
in 1 mg/ml protease X (Sigma Aldrich, Zwijndrecht, the Nether-
lands) for 90 min at 37uC, and stored in RNA lysis buffer at
280uC until further processing. Total messenger RNA was
isolated from the epidermis only, using GenElute Mammalian
Total RNA Miniprep kit (Sigma Aldrich). RNA purity and
integrity was verified by scanning with an Agilent 2100
Bioanalyzer using RNA 6000 Nano LabChip.
Array hybridization and analysis
For hybridization on gene expression arrays, RNA samples of
individual patients were pooled. Patients were divided into two
groups in order to have duplicate arrays for each time point and
condition. Biotinylated target RNA was prepared from the pooled
(1 mg) total RNA, and hybridized on GeneChip Human Genome
U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Array
hybridization and scanning was performed as described previously
[29]. The data were read and robust multichip analysis (RMA)
[30] was used to remove the background and normalize the data
across arrays [31]. These values were log2-transformed for further
analysis, yielding numbers between 0 and 16. A two-way ANOVA
with factors ‘‘probe’’ and ‘‘condition’’ was used for each probeset
to calculate both average expression levels per condition [32] and
a p-value for the difference between conditions. The resulting p-
values were adjusted for multiple testing using Sˇida´k step-up
adjustment [33]. Genes were considered differentially expressed
when p-values were ,0.05.
Gene expression analysis of isolated hair follicles of GATA32/2
mice was perfomed as described previously [9]. Microarray data
complied with the MIAME regulations and are available in
ArrayExpress (accession code: 5988). Functional annotation was
performed using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) [34].
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Quantitative RT-PCR
RNA of individual patients was transcribed into cDNA, and
RT-PCR was performed as described previously [35]. ABL1 was
used as a housekeeping control gene. Sequences of newly designed
primers and probe numbers of the Exiqon probe library system
(Exiqon, Vedbaek, Denmark) are listed in Table 1.
Mice and treatments
Induction of psoriasiform skin inflammation by application of
imiquimod on BALB/c and LacZ knock in GATA3 mice [36] was
performed as described previously [22]. Briefly, mice were treated
daily with imiquimod on the shaved back skin for 5 days. Every
other day, starting on the first day of the experiment, mice were
irradiated with a Waldmann NB-UVB irradiation device equipped
with TL-01 UV 236-01 lamps (Waldmann Medizintechnik,
Villingen-Schwenningen, Germany), or were sham irradiated.
The applied starting UVB dose was 70% of the minimal erythema
dose (MED) and it was increased by 10% each treatment. Scoring
of the severity of skin inflammation was performed as described
previously [22]. On day 6, mice were sacrificed and 3 mm biopsy
samples were taken from the back skin. Total RNA was isolated,
transcribed into cDNA, and the expression of GATA3 was
determined by RT-PCR, using ABL1 as a housekeeping control
gene.
To determine the MED in BALB/c mice, animals were
irradiated with increasing doses of NB-UVB. Ear thickness was
measured with a micrometer (Mitutoyo, Veenendaal, the Nether-
lands) before the UVB irradiation and 48 h later. The lowest NB-
UVB dose where ear thickness was significantly increased was
1680 mJ/cm2. 70% of this dose (thus 70% of the MED) was used
as the starting dose in further experiments.
Prior to the irradiation experiment one of the LacZ knockin
GATA3 mice was critically bitten and had to be sacrificed. We
took advantage of this unintentional skin wounding to assess
whether this insult and concomitant skin regeneration affected
GATA3 expression. The wounded back skin of this mouse as well
as unaffected adjacent skin was embedded in Tissue-Tec
embedding medium (Sakura, Zoeterwoude, the Netherlands) and
snap-frozen.
Immunohistochemistry, X-Gal staining and BrdU labelling
For immunofluorescent staining, cryosections or cells were fixed
for 10 min in 4% paraformaldehyde (PFA) in PBS. Primary
antibodies included anti-b-defensin 2 (1:100; Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-GATA3 (1:100; Santa Cruz
Biotechnology), anti-phosphorylated STAT3 (1:50; Cell Signaling
Technology Inc, Danvers, MA) and K10 (mouse 1:50; Sigma,
clone k8.60). Relevant FITC-, TxR- or HRP-conjugated antibod-
ies (1:100, Abcam) were used to detect primary antibodies. All
fluorescent images were taken with an Axio Imager (Zeiss)
fluorescence microscope.
Mice were injected with 50 mg/kg bodyweight 5-bromo-29-
deoxyuridine (BrdU) and sacrificed 2 h later. Cryosections were
fixed for 10 min in 4% PFA in PBS and washed three times for
5 min in PBS. As block/diluent was used: 1% BSA, 0.05% Tween
in PBS. For BrdU immunohistochemistry with BrdU (mouse
1:100; DAKO, clone Bu20a), tissue samples were fixed in 4% PFA
in PBS at 4uC overnight. Skin samples were subsequently
embedded in paraffin and sectioned at 5 mm. After deparaffination
sections were boiled in 0.01 M citrate buffer (pH 6.0) for 15 min
prior to incubation with primary antibody. Sections were analyzed
and photographed with an Olympus BX40 light microscope.
For X-gal staining sections were fixed 1 min in 0.5%
glutaraldehyde, 1% PFA, washed in PBS and incubated in X-gal
staining solution (5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6*3H20,
2 mM MgCl2, 0.01% natrium-deoxycholate, 0.02% NP40, 1 mg/
ml bromo-chloro-indolyl-galactopyranoside) for 5 h at room
temperature. Sections then were fixed in 4% PFA for 10 min
and counterstained with neutral red.
Results
Epidermal GATA3 expression is decreased in human
psoriatic lesions and in psoriasiform dermatitis in mice
Previous studies showed that GATA3 is downregulated in lesional
psoriatic epidermis ([4], Ra´cz et al, submitted). To validate this
finding, GATA3 mRNA expression was measured by quantitative
RT-PCR in the epidermis of skin biopsies from patients with
psoriasis and skin from healthy controls. A 5-fold (range 3–12-fold)
lower expression of GATA3 was observed in lesional epidermis
compared to non-lesional epidermis (Figure 1B). GATA3 expression
was also determined in situ at the protein level, in skin biopsies from
healthy individuals, as well as in lesional and non-lesional skin
biopsies of patients with psoriasis. In healthy control skin GATA3
expression was present in all epidermal layers except the basal layer
(Figure 1A). In non-lesional psoriatic skin, GATA3 expression was
also visible in the basal layer, while in lesional psoriatic skin overall
GATA3 expression was decreased and GATA3 was only present at
low level in a few suprabasal cells (Figure 1A).
Next we assessed the expression of GATA3 in imiquimod-
induced psoriasiform dermatitis in mice. Daily application of the
TLR7/8 agonist imiquimod cream (AldaraH) on mouse back skin
induces skin inflammation that strongly resembles human psoriasis
in terms of phenotypic and histological features [22]. Mean
relative GATA3 mRNA expression as measured by RT-PCR,
using ABL1 as a control housekeeping gene, was 4.60 in the
control mice (range 3.10–9.22, n = 5), whereas in mice treated with
imiquimod mean relative GATA3 expression was 1.96 (range
1.16–3.26, n = 5). Thus, GATA3 mRNA expression measured by
RT-PCR was 2.35-fold lower in the psoriasiform dermatitis lesions
than in control mouse skin (p = 0.016, determined using the Mann-
Whitney U test) (Figure 1C).
Table 1. Primers and probes for RT-PCR.
Gene Forward primer Reverse primer Probe
hGATA3 GCTTCGGATGCAAGTCCA GCCCCACAGTTCACACACT Nr. 81
mGATA3 CATTACCACCTATCCGCCCTATG CACACACTCCCTGCCTTCTGT CGAGGCCCAAGGCACGATCCAG
hGAPDH TCCACTGGCGTCTTCAC GGCAGAGATGATGACCCTTTT Nr. 451
h/mABL1 TGGAGATAACACTCTAAGCATAACTAAAGGT GATGTAGTTGCTTGGGACCCA CCATTTTTGGTTTGGGCTTCACACCATT
1Probe from the Exiqon probe library system (Exiqon, Vedbaek, Denmark).
doi:10.1371/journal.pone.0019806.t001
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GATA3 expression in psoriasis is upregulated by effective
treatment of the disease
NB-UVB phototherapy is a standard and effective treatment
modality for human psoriasis. We evaluated whether NB-UVB
treatment of patients with psoriasis would induce epidermal
GATA3 expression towards the levels in normal skin. We
therefore measured GATA3 expression by RT-PCR in patients
with psoriasis undergoing standard NB-UVB therapy. Indeed,
GATA3 mRNA expression increased gradually during the course
of NB-UVB treatment, correlating inversely with the clinical PASI
score (Figure 2A).
Similarly, NB-UVB treatment also inhibited the severity of the
psoriasiform dermatitis in mice by approximately 40% (p = 0.034
as determined with the Mann-Whitney U test, n = 3 mice per
group) (Figure 2B). Accordingly, histological examination showed
decreased epidermal thickness, improved epidermal differentiation
and a significantly reduced number of proliferating BrdU+ cells in
NB-UVB-treated as compared to control mouse skin (Figure 2D,
E). NB-UVB treatment clearly reduced markers of psoriasis
activity such as epidermal phosphorylated STAT3, dendritic cell
and neutrophilic granulocyte infiltrates and angiogenesis [5].
Thus, NB-UVB irradiation of imiquimod-treated mouse skin
results in improvement of psoriasiform dermatitis, as assayed by
clinical, histological and immunohistochemical parameters.
We next assessed GATA3 expression during NB-UVB irradi-
ation of murine psoriasiform dermatitis. Therefore psoriasiform
dermatitis was induced in GATA3-LacZ knockin mice [36],
followed by irradiation every other day with NB-UVB or sham
UVB treatment. In these mice, the expression of the LacZ product
X-Gal depends on GATA3 promoter activity. On day 6 mice were
sacrificed and GATA3 expression was assayed by X-Gal staining
of back skin sections. X-Gal staining was decreased in the
psoriasiform mouse skin, and was clearly re-induced by NB-UVB
irradiation (Figure 2C). In conclusion, successful treatment of
psoriasis patients and of murine psoriasiform skin inflammation is
associated with upregulation of GATA3 expression, which
parallels clinical improvement.
GATA3 expression is downmodulated during epidermal
regeneration
The epidermal response in psoriasis shares many similarities
with the epidermal regeneration program upon wounding [23].
During epidermal regeneration not only keratinocyte proliferation
and dermal angiogenesis are stimulated, but also an inflammatory
and antimicrobial response is initiated to prevent infection through
the injured epidermal barrier. We asked whether decreased
keratinocyte GATA3 expression was specific to psoriatic inflam-
mation or could also be seen during epidermal regeneration. First,
epidermal barrier disruption was induced in non-lesional skin of
patients with psoriasis by repeated tape stripping. Before tape
stripping and 5 h later, skin biopsies were taken from the tape-
stripped area, the epidermis was separated from the dermis, and
mRNA expression of epidermal GATA3 quantitated. Skin tape
stripping downregulated GATA3 expression in the epidermis by a
mean of 80% from baseline levels (p = 0.03 using the Wilcoxon
signed rank test, n = 6 patients) (Figure 3A).
We additionally investigated GATA3 expression during wound
healing by performing X-Gal staining on sections taken from the
Figure 1. Epidermal GATA3 expression is decreased in psoriatic lesions. A. GATA3 protein is present in the nuclei of the suprabasal layers of
the epidermis in normal skin. In non-lesional psoriatic skin GATA3 is expressed in all epidermal layers whereas in lesional skin sporadic GATA3
expression is observed. The borders of the epidermis are depicted. Scale bar: 100 mm. B. Expression of GATA3 mRNA was almost seven-fold lower in
lesional skin (PP) compared to non-lesional skin (PN). Epidermal GATA3 mRNA expression was determined by RT-PCR using ABL1 as a housekeeping
control gene. In each patient, GATA3 expression in lesional skin is calculated relative to the expression in non-lesional skin. Bars represent mean +/2
SEM (n = 5 patients). C. GATA3 mRNA expression in imiquimod-induced psoriasiform dermatitis in mice is lower than in control back skin of BALB/c
mice. Bars indicate the mean +/2 SEM (n= 3 mice per group).
doi:10.1371/journal.pone.0019806.g001
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Figure 2. NB-UVB phototherapy induces GATA3 expression. A. GATA3 expression is upregulated during the course of NB-UVB phototherapy
in patients with psoriasis. 3 mm biopsies were taken from lesional (PP) and non-lesional skin of patients with psoriasis before, during and after NB-
UVB phototherapy. Epidermal GATA3 mRNA expression was determined with RT-PCR using ABL1 as a housekeeping control gene. Bars represent
mean +/2 SEM (n = 5 patients). The interrupted line shows change in the PASI score, relative to the baseline score. B. Psoriasiform dermatitis was
induced in BALB/c mice by daily treatment with IMQ cream (or control cream) on the shaved back skin, and irradiated or sham-irradiated every other
day with NB-UVB, starting on the first day of imiquimod treatment. Erythema, scaling, and thickness of the back skin were scored daily on a scale from
0 to 4. The cumulative score (erythema plus scaling plus thickness) is shown. Symbols indicate mean score +/2 SEM of three mice per group. C. X-gal
staining (blue) of GATA3LacZ skin biopsies from mice with psoriasiform dermatitis with or without NB-UVB treatment. D. BrdU incorporation in
keratinocytes in the back skin was detected by immunohistochemistry. The bars represent the mean number of BrdU positive cells +/2 SD. E.
Biopsies from psoriasiform dermatitis on the back skin of the mice were stained for Keratin 1/10. Scale bars on panels C, D and E: 100 mm.
doi:10.1371/journal.pone.0019806.g002
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wounded back skin of GATA3 LacZ knock in mice. GATA3 was
expressed in all epidermal layers of the intact epidermis, whereas
in the center of the wound only few X-Gal positive keratinocytes
were seen (Figure 3B). In conclusion, GATA3 expression is
downmodulated in the regenerating epidermis after wounding and
tape stripping, and in psoriasis.
GATA3 downregulation is associated with decreased
expression of TNFAIP3, Jagged and AP2 transcription
factors in keratinocytes
To identify other transcription factors associated with down-
modulated GATA3 expression in psoriatic epidermis, we com-
pared the gene expression profiles from epidermis-specific
GATA3-deficient mice [9] with that of lesional epidermis of
patients with psoriasis. For this, two different comparisons were
made: A: RNA from mouse hair follicles of wild type versus
GATA32/2 mice. B: RNA from human epidermis from non-
lesional versus lesional skin. After this, the two lists of differentially
expressed genes were crossed, thereby selecting genes that were
either down- or up-regulated both in GATA32/2 epidermis
(when compared to WT mouse epidermis), as wells as in lesional
psoriatic epidermis (when compared to non-lesional epidermis).
In the epidermis of epidermis-specific GATA32/2 mice 5922
genes were differentially expressed when compared to wild type
mice (p,0.05, $1.2-fold up- or downregulated [9]). In human
lesional psoriatic epidermis, characterized by low GATA3
expression, 2412 genes were differentially expressed when
compared to non-lesional epidermis (p,0.05, $1.2-fold up- or
downregulated) [5]. Genes were identified that were upregulated
in both GATA3-deficient mouse skin and in lesional psoriatic
skin (77 genes), or were downregulated in both (97 genes)
(Table 2, Table S1). The resulting group of genes included
negative regulators of inflammation, such as the psoriasis
susceptibility gene TNFAIP3 [21,37] and the Notch ligand
jagged 2 [38], and also genes regulating epidermal differentia-
tion, such as the transcription factor AP2-a (TFAP2A) [39], and
the apoptosis-inducing FAS molecule. Expression of several
other transcription factors was regulated in a coordinated fashion
with GATA3 (Table S1), e.g. FOXP1, FOXO1, FOXN3,
KLF13 and SNAI2, factors mainly involved in organ develop-
ment and differentiation.
Additionally, the list of 174 genes was subjected to gene
annotation using the DAVID Gene Annotation Tool. This
comparison showed that low GATA3 expression in both
human psoriatic and GATA3-deficient murine epidermis
coincided with altered expression of genes involved in cell
differentiation, cell proliferation and apoptosis (Table 2,
Table S1).
Figure 3. GATA3 expression is decreased in the regenerating epidermis. A. Six psoriatic patients underwent repeated tape stripping to
induce skin activation and regeneration. Directly before and 5 h after tape stripping biopsies were taken and epidermal GATA3 expression was
determined using RT-PCR, relative to ABL1 as a housekeeping control gene. Relative expression values of individual patients are shown. B. GATA3
expression is downregulated in the healing wound of mouse skin. X-gal staining (blue) of wounded skin of a GATA3LacZ mouse shows
downregulation of the LacZ transgene under control of GATA3 in the highly proliferative zone of the healing wound. Arrows indicate X-Gal positive
cells; the border between regenerating and adjacent normal skin is marked. Scale bar: 200 mm.
doi:10.1371/journal.pone.0019806.g003
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GATA3 in proliferating, differentiating and cell cycle
arrested keratinocytes
The expression of GATA3 was investigated in relationship to
keratinocyte differentiation and proliferation by immunofluores-
cent staining of undifferentiated, growth-arrested and calcium-
induced differentiated keratinocytes. In differentiating keratino-
cytes GATA3 staining was localized only in the nucleus, whereas
in normal proliferating keratinocytes GATA3 staining was present
in the nuclei and in the cytoplasm (Figure 4A, B, D). In addition,
cell cycle arrest was induced in keratinocytes by culturing them in
the presence of 3 ng/ml TGF-b1 at low and high Ca2+
conditions. Interestingly, GATA3 staining in TGF-b1-treated cells
was almost completely localized to the cytoplasm, indicating lack
of signaling (Figure 4C,D).
In conclusion, in differentiated keratinocytes GATA3 is
transcriptionally active, whereas no nuclear GATA3 could be
observed during cell cycle arrest, indicating that GATA3 is
important during keratinocyte differentiation and proliferation.
The Th2 cytokine IL-4 induces GATA3 in human
epidermal cells
We next asked which cytokines in psoriatic lesions could induce
or downmodulate GATA3. We therefore stimulated skin biopsies
from healthy volunteers ex vivo with different cytokines important
in the pathogenesis of psoriasis and measured epidermal GATA3
mRNA. Human skin biopsies were cultured with IFN-a, [40],
IFN-c, or IL-22, prototypic Th1 and Th17 cytokines, respectively,
and the prototypic Th2 cytokine IL-4. IL-4 caused a 7-fold
induction of GATA3 expression (range 4.2–10.7, n = 6 healthy
donors). IFN-c slightly induced GATA3 expression (1.7-fold;
range 1.2–2.7, n = 8 healthy donors), whereas IFN-a and IL-22
had no significant effect (Figure 5). TNF-a, IL-17A, IL-23, IL-1b,
oncostatin M, nerve growth factor (NGF), substance P and
combinations of these also did not induce or suppress GATA3 (data
submitted).
Discussion
Our results show that the epidermal expression of the
transcription factor GATA3 is consistently decreased in psoriasis,
in psoriasiform dermatitis in mice, and during epidermal wound
healing. Our finding that epidermal GATA3 expression is
downmodulated in both psoriasis and epidermal regeneration is
consistent with previously described parallels between these
conditions. It identifies GATA3 as a crucial transcription factor
in keratinocyte homeostasis, activation and proliferation. We also
show that in healthy human skin explants the Th2 cytokine IL-4
was the only cytokine, out of a broad array of cytokines critical in
psoriasis, able to significantly and effectively induce GATA3
expression in the epidermis.
Although downmodulated GATA3 levels have been reported in
microarray studies of psoriasis [4,41,42], its role and modulation of
its expression in human skin was not investigated in great detail.
Polymorphisms in the GATA3 gene or genetic linkage have not
been reported for psoriasis, but have been found for atopic
Table 2. List1 of genes differentially expressed in both psoriasis and GATA3 2/2 mice.
Symbol Cell differentiation
Fold change
human
Fold change
mouse Up/down
SOD2 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL 6.0 1.2 U
ALDH1A3 ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3 3.9 1.5 U
TXNDC5 THIOREDOXIN DOMAIN CONTAINING 5 2.5 1.3 U
EHF ETS HOMOLOGOUS FACTOR 2.3 1.3 U
CTSB CATHEPSIN B 2.1 1.3 U
Apoptosis
SOD2 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL 6.0 1.2 U
ALDH1A3 ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3 3.9 1.5 U
TXNDC5 THIOREDOXIN DOMAIN CONTAINING 5 2.5 1.3 U
CTSB CATHEPSIN B 2.1 1.3 U
TNFAIP3 TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 3 2.6 1.3 D
Transcription regulation
TSC22D1 TSC22 DOMAIN FAMILY, MEMBER 1 3.0 1.7 D
EHF ETS HOMOLOGOUS FACTOR 2.3 1.3 U
HLF HEPATIC LEUKEMIA FACTOR 2.3 1.5 D
NFIB NUCLEAR FACTOR I/B 2.3 1.4 D
KAT2B K(LYSINE) ACETYLTRANSFERASE 2B 2.2 1.7 D
Other
DSC2 DESMOCOLLIN 2 4.0 1.9 U
TF TRANSFERRIN 2.2 2.0 U
LNX1 LIGAND OF NUMB-PROTEIN X 1 4.3 1.6 D
INSIG2 INSULIN INDUCED GENE 2 2.9 1.4 D
IGFBP5 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 2.7 1.3 D
1Top five genes per functional category are listed. For the complete list see Table S1.
doi:10.1371/journal.pone.0019806.t002
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dermatitis. The latter association is not unexpected since this
chronic inflammatory skin disease is linked to a Th2 signature
[43].
Most of our current insight into the function of GATA3
originates from T cell biology, whereas much less is known about
GATA3 molecular function in keratinocytes. In T cells GATA3
determines Th2 cell differentiation and selectively activates the
promoters of IL-4, IL-5, and IL-13 through chromatin remodel-
ling. For the latter, GATA3 must translocate from the cytoplasm
into the nucleus to access its target genes. Here we show that in
keratinocytes GATA3 is strongly induced by IL-4. Psoriasis is
currently viewed as a predominantly Th1/Th17 disease, where
the Th1 cytokines (IFN-c) and Th17 cytokines (IL-17, IL-22)
together with IL-23 suppress the production of IL-4 in T
lymphocytes. Perhaps the relative lack of IL-4 in psoriatic lesions
contributes to the reduction of GATA3 expression in the
epidermis (and also to the upregulation of the IL-4 receptor on
psoriatic keratinocytes [44]). In a clinical trial IL-4 was previously
shown to effectively clear psoriasis [45]. In spite of the promising
results, IL-4 was, not further developed into clinical practice for
commercial reasons.
At the time, the beneficial effect of IL-4 in psoriasis was
attributed to the Th2-inducing and Th1 inhibitory capacity of IL-
4 together with modulation of IL-23 production by dermal
inflammatory APC [46]. Our results provide a novel mechanism
in keratinocytes by which IL-4 improves psoriasis.
To identify molecules that are co-ordinately regulated with
GATA3 in psoriasis, we determined the overlap between genes
differentially regulated in epidermis-specific GATA3 deficient
mice and genes that were differentially expressed in human
lesional psoriatic skin compared to non-lesional skin. The resulting
group of genes included negative regulators of inflammation, such
as the psoriasis susceptibility gene TNFAIP3 [21,37] and the
Notch ligand jagged 2 [38], and also genes regulating epidermal
differentiation, such as the transcription factor AP2-a (TFAP2A)
[39], and the apoptosis-inducing FAS molecule. In addition, the
Figure 4. Nuclear translocation of GATA3 in differentiating keratinocytes, but not during cell cycle arrest. Primary human epidermal
keratinocytes were cultured on chamber slides. When cells were approximately 75% confluent, 1.2 mM CaCl2 (B, D) and/or 3 ng/ml TGF-b1 (C, D)
were added to the culture medium. After 24 h cells were fixed and immunofluorescent staining for GATA3 protein (pink) was performed. E. GATA3
positive cell nuclei were counted and are shown as a percentage of the total number of cell nuclei. Scale bar: 20 mm.
doi:10.1371/journal.pone.0019806.g004
Figure 5. IL-4 induces the expression of GATA3 in human
epidermis. Three mm biopsies from normal human skin were cultured
in the presence of proinflammatory cytokines for 24 h. The epidermis
was separated from the dermis and GATA3 expression was measured
by RT-PCR in epidermal RNA, using ABL1 as a housekeeping control
gene. Bars represent mean +/2 SEM (n = 4 (IFN-a, IL-22), n = 6 (IL-4) or
n = 8 (IFN-c) healthy donors).
doi:10.1371/journal.pone.0019806.g005
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transcription factors FOXN3 and FOXO1, regulating cell
differentiation and the cell cycle, were also downregulated together
with GATA3. These molecules play regulatory roles in organ
development [47], metabolism [48] and cell proliferation [49],
respectively. Together with the induction of GATA3, AP2-a
(TFAP2A), the anti-inflammatory TNFAIP3 and Jagged 2
molecules were also induced in lesional psoriatic skin by NB-
UVB. Induction of these molecules might contribute to the anti-
psoriatic effects of NB-UVB.
In conclusion, this study shows that the epidermal expression of
the transcription factor GATA3 is consistently downregulated
under conditions of keratinocyte hyperproliferation and altered
differentiation such as in psoriasis, in murine psoriasiform
dermatitis and in wound healing. Our results indicate that
induction of GATA3 expression in keratinocytes may be a novel
therapeutic strategy in the treatment of psoriasis.
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